Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of rosuvastatin (up-titrated to a dose of
40mg/day) compared to placebo on cardiac remodelling, estimated by change in left ventricular
ejection fraction on radionuclide ventriculography, at 26 weeks post randomisation from
baseline.